.jpg)
.jpg)
01 Apr, 2020
CNS Pharmaceuticals Development Partner, WPD Pharmaceuticals, Reports Active Compound in Licensed Drug Candidate Reduces COVID19 Replication in Vitro by 100%
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) in collaboration with its development partner WPD Pharmaceuticals Inc. intends to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the co..
@Newsletter
Sign Up for Weekly UpdatesOpt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!
No articles found.
.jpg){kind=small}
All rights reserved.
No portion of Financialinsiders.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law. By accessing any information beyond this page, you agree to abide by the Privacy Policy and Terms of Use (Disclaimer).